Why the Paradigm (ASX:PAR) share price is sinking 14% on Tuesday

This biotech share is having a day to forget…

| More on:
asx share price falling lower represented by investor wearing paper bag on head with sad face

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is under significant pressure on Tuesday morning.

At the time of writing, the biopharmaceutical company's shares are down 14.5% to $1.90.

This decline means the Paradigm share price is now down 35.5% over the last 12 months.

Why is the Paradigm share price crashing?

Investors have been selling down the Paradigm share price on Tuesday following the release of an update on the Investigational New Drug (IND) application it submitted to the US Food and Drug Administration (FDA) in March.

As you might have guessed from the weakness in the Paradigm share price, the update was not an overly positive one.

What's been happening?

In June, Paradigm submitted a response to the FDA's six questions relating to Paradigm's IND submission.

According to today's announcement, the company has now received a written response from the US FDA. This reveals that the regulator has accepted Paradigm's responses to five of its six questions.

As a result, the FDA requires further clarification on one remaining question. This is in regard to the non-clinical interpretation and clinical mitigation relating to one of Paradigm's recently completed GLP non-clinical toxicology studies.

Paradigm notes that it conducted 26 non-clinical studies in 2020 at the request of the US FDA. Of the 26 non-clinical studies conducted, the FDA is seeking clarification on only one rat study.

Paradigm will now work with expert clinical and non-clinical consultants to prepare a response. It anticipates this will be submitted within a month.

Paradigm's Chief Medical Officer, Dr Donna Skerrett, remains optimistic that this outstanding question can be resolved.

She explained: "For new indications that impact large populations, such as osteoarthritis, a thorough and iterative process with the FDA for initiating the pivotal registration studies is common practice. Even though the pace of progressing the clearance process has been slowed due to COVID-19 resulting in all communications being written, we are confident that we can address the FDA's one remaining question. We look forward to resolving the one outstanding question with the FDA and moving froward with our pivotal program in the US, Europe and Australia."

However, judging by the Paradigm share price performance today, some investors aren't as confident as the company is.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Fallers

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Beetaloo, Botanix, Cobram Estate, and Origin Energy shares are falling today

These shares are having a poor session on Tuesday. But why?

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Antipa Minerals, Northern Star, Pilbara Minerals, and Synlait Milk shares are falling today

These shares are starting the week in the red. But why?

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why Evolution Mining, G8 Education, Lottery Corp, and Lynas shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

Two men in hard hats and high visibility jackets look together at a laptop screen at a mine site.
Gold

Down 50% in a year, time to pounce on this beaten-down ASX 200 gold stock?

A leading expert offers his verdict on this beaten-down ASX 200 gold miner.

Read more »

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why CBA, G8 Education, JB Hi-Fi, and Vault Minerals shares are falling today

These shares are falling on Thursday. But why?

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Fallers

These were the worst ASX 200 shares to buy in June

These shares took a tumble last month. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Domino's, Helia, Qantas, and Zip shares are sinking today

These shares are having a tough time on hump day. But why?

Read more »

A sad man looks at his computer screen as he holds a slice of pizza in his hand with an open pizza box in front of him on his desk.
Share Fallers

Why did the Domino's share price just crash 17%?

ASX investors just sent Domino’s shares tumbling more than 17% today. But why?

Read more »